Neuropeptide y receptors: How to get subtype selectivity

Frontiers in Endocrinology

Volumn 4, Issue FEB, 2013, Pages

  Pedragosa Badia, Xavier ^a   Stichel, Jan ^a   Beck Sickinger, Annette G ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

GPCR; Ligand side; NPY; Receptor side; Subtype selectivity; YR

Indexed keywords

1 NAPHTHALENESULFONIC ACID [4 [(4 AMINO 2 QUINAZOLINYLAMINO) METHYL] CYCLOHEXYLMETHYL] AMIDE; GR 231118; N [2 [1, 2 DIHYDRO 3, 5 (4H) DIOXO 1, 2 DIPHENYL 1, 2, 4 TRIAZOL 4 YL] ETHYL] N2 [[1 [2 [4 [5, 11 DIHYDRO 6 (6H) OXODIBENZ [B, E] AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL] CYCLOPENTYL] ACETYL] ARGININAMIDE; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y3 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BINDING AFFINITY; CYCLIZATION; DRUG SELECTIVITY; GENE MUTATION; HUMAN; MUTAGENESIS; NEUROTRANSMITTER RELEASE; NONHUMAN; OBESITY; PROTEIN CONFORMATION; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

EID: 84881654515     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2013.00005     Document Type: Review

References (125)

1. Akerberg, H., Fallmar, H., Sjodin, P., Boukharta, L., Gutierrez-De-Teran, H., Lundell, I., et al. (2010). Mutagenesis of human neuropeptide Y/peptide YY receptor Y2 reveals additional differences to Y1 in interactions with highly conserved ligand positions. Regul. Pept. 163, 120-129.
2. Antal-Zimanyi, I., Bruce, M. A., Leboulluec, K. L., Iben, L. G., Mattson, G. K., Mcgovern, R. T., et al. (2008). Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. Eur. J. Pharmacol. 590, 224-232.
3. Asakawa, A., Inui, A., Ueno, N., Fujimiya, M., Fujino, M. A., and Kasuga, M. (1999). Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice. Peptides 20, 1445-1448.
4. Asakawa, A., Inui, A., Yuzuriha, H., Ueno, N., Katsuura, G., Fujimiya, M., et al. (2003). Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124, 1325-1336.
5. Balasubramaniam, A. (2002). Clinical potentials of neuropeptide Y family of hormones. Am. J. Surg. 183, 430-434.
6. Balasubramaniam, A., Dhawan, V. C., Mullins, D. E., Chance, W. T., Sheriff, S., Guzzi, M., et al. (2001). Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY(28-36)-NH2 (BW1911U90). J. Med. Chem. 44, 1479-1482.
7. Baldock, P. A., Lee, N. J., Driessler, F., Lin, S., Allison, S., Stehrer, B., et al. (2009). Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS ONE 4:e8415. doi: 10.1371/journal.pone.0008415
8. Baldock, P. A., Sainsbury, A., Couzens, M., Enriquez, R. F., Thomas, G. P., Gardiner, E. M., et al. (2002). Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest. 109, 915-921.
9. Bard, J. A., Walker, M. W., Branchek, T. A., and Weinshank, R. L. (1995). Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY. J. Biol. Chem. 270, 26762-26765.
10. Beck-Sickinger, A. G. (1997). "Synthesis of conformationally restricted peptides," in Neuropeptide Protocols, eds G. B. Irvine and C. H. Williams (Totowa, NJ: Humana Press), 61-74.
11. Beck-Sickinger, A. G., and Jung, G. (1995). Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors. Biopolymers 37, 123-142.
12. Beck-Sickinger, A. G., Wieland, H. A., Wittneben, H., Willim, K. D., Rudolf, K., and Jung, G. (1994). Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations. Eur. J. Biochem. 225, 947-958.
13. Beck, A., Jung, G., Gaida, W., Koppen, H., Lang, R., and Schnorrenberg, G. (1989). Highly potent and small neuropeptide Y agonist obtained by linking NPY 1-4 via spacer to alpha-helical NPY 25-36. FEBS Lett. 244, 119-122.
14. Berglund, M. M., Fredriksson, R., Salaneck, E., and Larhammar, D. (2002). Reciprocal mutations of neuropeptide Y receptor Y2 in human and chicken identify amino acids important for antagonist binding. FEBS Lett. 518, 5-9.
15. Blomqvist, A. G., and Herzog, H. (1997). Y-receptor subtypes - how many more? Trends Neurosci. 20, 294-298.
16. Blomqvist, A. G., Soderberg, C., Lundell, I., Milner, R. J., and Larhammar, D. (1992). Strong evolutionary conservation of neuropeptide Y: sequences of chicken, goldfish, and Torpedo marmorata DNA clones. Proc. Natl. Acad. Sci. U.S.A. 89, 2350-2354.
17. Blundell, T. L., Pitts, J. E., Tickle, I. J., Wood, S. P., and Wu, C. W. (1981). X-ray analysis (1. 4-A resolution) of avian pancreatic polypeptide: small globular protein hormone. Proc. Natl. Acad. Sci. U.S.A. 78, 4175-4179.
18. Boguszewski, C. L., Paz, G., and Velloso, L. A. (2010). Neuroendocrine body weight regulation: integration between fat tissue, gastrointestinal tract, and the brain. Endokrynol. Pol. 61, 194-206.
19. Bonaventure, P., Nepomuceno, D., Mazur, C., Lord, B., Rudolph, D. A., Jablonowski, J. A., et al. (2004). Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a small molecule antagonist of the neuropeptide Y Y2 receptor. J. Pharmacol. Exp. Ther. 308, 1130-1137.
20. Bonini, J. A., Jones, K. A., Adham, N., Forray, C., Artymyshyn, R., Durkin, M. M., et al. (2000). Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J. Biol. Chem. 275, 39324-39331.
21. Bromee, T., Sjodin, P., Fredriksson, R., Boswell, T., Larsson, T. A., Salaneck, E., et al. (2006). Neuropeptide Y-family receptors Y6 and Y7 in chicken. Cloning, pharmacological characterization, tissue distribution and conserved synteny with human chromosome region. FEBS J. 273, 2048-2063.
22. Brothers, S. P., Saldanha, S. A., Spicer, T. P., Cameron, M., Mercer, B. A., Chase, P., et al. (2010). Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening. Mol. Pharmacol. 77, 46-57.
23. Caberlotto, L., Fuxe, K., Sedvall, G., and Hurd, Y. L. (1997). Localization of neuropeptide Y Y1 mRNA in the human brain: abundant expression in cerebral cortex and striatum. Eur. J. Neurosci. 9, 1212-1225.
24. Cabrele, C., and Beck-Sickinger, A. G. (2000). Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. J. Pept. Sci. 6, 97-122.
25. Cabrele, C., Langer, M., Bader, R., Wieland, H. A., Doods, H. N., Zerbe, O., et al. (2000). The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats. J. Biol. Chem. 275, 36043-36048.
26. Cabrele, C., Wieland, H. A., Koglin, N., Stidsen, C., and Beck-Sickinger, A. G. (2002). Ala31-Aib32: identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y5-receptor. Biochemistry 41, 8043-8049.
27. Castan, I., Valet, P., Larrouy, D., Voisin, T., Remaury, A., Daviaud, D., et al. (1993). Distribution of PYY receptors in human fat cells: an antilipolytic system alongside the alpha 2-adrenergic system. Am. J. Physiol. 265, E74-E80.
28. Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G., Thian, F. S., Kobilka, T. S., et al. (2007). High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318, 1258-1265.
29. Criscione, L., Rigollier, P., Batzl-Hartmann, C., Rueger, H., Stricker-Krongrad, A., Wyss, P., et al. (1998). Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J. Clin. Invest. 102, 2136-2145.
30. Doods, H., Gaida, W., Wieland, H. A., Dollinger, H., Schnorrenberg, G., Esser, F., et al. (1999). BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur. J. Pharmacol. 384, R3-R5.
31. Eckard, C. P., Cabrele, C., Wieland, H. A., and Beck-Sickinger, A. G. (2001). Characterisation of neuropeptide Y receptor subtypes by synthetic NPY analogues and by anti-receptor antibodies. Molecules 6, 448-467.
32. Edelsbrunner, M. E., Painsipp, E., Herzog, H., and Holzer, P. (2009). Evidence from knockout mice for distinct implications of neuropeptide-Y Y2 and Y4 receptors in the circadian control of locomotion, exploration, water and food intake. Neuropeptides 43, 491-497.
33. Erondu, N., Wadden, T., Gantz, I., Musser, B., Nguyen, A. M., Bays, H., et al. (2007). Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring) 15, 895-905.
34. Fallmar, H., Akerberg, H., Gutierrez-De-Teran, H., Lundell, I., Mohell, N., and Larhammar, D. (2011). Identification of positions in the human neuropeptide Y/peptide YY receptor Y2 that contribute to pharmacological differences between receptor subtypes. Neuropeptides 45, 293-300.
35. Ferrier, L., Segain, J. P., Bonnet, C., Cherbut, C., Lehur, P. A., Jarry, A., et al. (2002). Functional mapping of NPY/PYY receptors in rat and human gastro-intestinal tract. Peptides 23, 1765-1771.
36. Flood, J. F., and Morley, J. E. (1989). Dissociation of the effects of neuropeptide Y on feeding and memory: evidence for pre- and postsynaptic mediation. Peptides 10, 963-966.
37. Fournier, A., Gagnon, D., Quirion, R., Cadieux, A., Dumont, Y., Pheng, L. H., et al. (1994). Conformational and biological studies of neuropeptide-Y analogs containing structural alterations. Mol. Pharmacol. 45, 93-101.
38. Fuhlendorff, J., Gether, U., Aakerlund, L., Langeland-Johansen, N., Thogersen, H., Melberg, S. G., et al. (1990). [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist. Proc. Natl. Acad. Sci. U.S.A. 87, 182-186.
39. Gehlert, D. R. (1998). Multiple receptors for the pancreatic polypeptide (PP-fold) family: physiological implications. Proc. Soc. Exp. Biol. Med. 218, 7-22.
40. Gerald, C., Walker, M. W., Criscione, L., Gustafson, E. L., Batzl-Hartmann, C., Smith, K. E., et al. (1996). A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382, 168-171.
41. Golombek, D. A., Biello, S. M., Rendon, R. A., and Harrington, M. E. (1996). Neuropeptide Y phase shifts the circadian clock in vitro via a Y2 receptor. Neuroreport 7, 1315-1319.
42. Gribkoff, V. K., Pieschl, R. L., Wisialowski, T. A., Van Den Pol, A. N., and Yocca, F. D. (1998). Phase shifting of circadian rhythms and depression of neuronal activity in the rat suprachiasmatic nucleus by neuropeptide Y: mediation by different receptor subtypes. J. Neurosci. 18, 3014-3022.
43. Haack, M., Enck, S., Seger, H., Geyer, A., and Beck-Sickinger, A. G. (2008). Pyridone dipeptide backbone scan to elucidate structural properties of a flexible peptide segment. J. Am. Chem. Soc. 130, 8326-8336.
44. Hankir, M. K., Parkinson, J. R., Minnion, J. S., Addison, M. L., Bloom, S. R., and Bell, J. D. (2011). Peptide YY 3-36 and pancreatic polypeptide differentially regulate hypothalamic neuronal activity in mice in vivo as measured by manganese-enhanced magnetic resonance imaging. J. Neuroendocrinol. 23, 371-380.
45. Hausman, G. J., Barb, C. R., and Dean, R. G. (2008). Patterns of gene expression in pig adipose tissue: insulin-like growth factor system proteins, neuropeptide Y (NPY), NPY receptors, neurotrophic factors and other secreted factors. Domest. Anim. Endocrinol. 35, 24-34.
46. Heilig, M. (2004). The NPY system in stress, anxiety and depression. Neuropeptides 38, 213-224.
47. Hipskind, P. A., Lobb, K. L., Nixon, J. A., Britton, T. C., Bruns, R. F., Catlow, J., et al. (1997). Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists. J. Med. Chem. 40, 3712-3714.
48. Hoffmann, S., Rist, B., Videnov, G., Jung, G., and Beck-Sickinger, A. G. (1996). Structure-affinity studies of C-terminally modified analogs of neuropeptide Y led to a novel class of peptidic Y1 receptor antagonist. Regul. Pept. 65, 61-70.
49. Holland-Nell, K., and Meldal, M. (2011). Maintaining biological activity by using triazoles as disulfide bond mimetics. Angew. Chem. Int. Ed. Engl. 50, 5204-5206.
50. Holliday, N. D., Michel, M. C., and Cox, H. M. (2004). "NPY receptor subtypes and their signal transduction" in Neuropeptide Y and Related Peptides, ed. M. C. Michel (Berlin: Springer), 45-73.
51. Jablonowski, J. A., Chai, W., Li, X., Rudolph, D. A., Murray, W. V., Youngman, M. A., et al. (2004). Novel non-peptidic neuropeptide Y Y2 receptor antagonists. Bioorg. Med. Chem. Lett. 14, 1239-1242.
52. Jain, M. R., Pu, S., Kalra, P. S., and Kalra, S. P. (1999). Evidence that stimulation of two modalities of pituitary luteinizing hormone release in ovarian steroid-primed ovariectomized rats may involve neuropeptide Y Y1 and Y4 receptors. Endocrinology 140, 5171-5177.
53. Kakui, N., Tanaka, J., Tabata, Y., Asai, K., Masuda, N., Miyara, T., et al. (2006). Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethy l)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor. J. Pharmacol. Exp. Ther. 317, 562-570.
54. Kanatani, A., Ishihara, A., Iwaasa, H., Nakamura, K., Okamoto, O., Hidaka, M., et al. (2000a). L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem. Biophys. Res. Commun. 272, 169-173.
55. Kanatani, A., Mashiko, S., Murai, N., Sugimoto, N., Ito, J., Fukuroda, T., et al. (2000b). Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 141, 1011-1016.
56. Kannoa, T., Kanatani, A., Keen, S. L., Arai-Otsuki, S., Haga, Y., Iwama, T., et al. (2001). Different binding sites for the neuropeptide Y Y1 antagonists 1229U91 and J-104870 on human Y1 receptors. Peptides 22, 405-413.
57. Keire, D. A., Kobayashi, M., Solomon, T. E., and Reeve, J. R. Jr. (2000a). Solution structure of monomeric peptide YY supports the functional significance of the PP-fold. Biochemistry 39, 9935-9942.
58. Keire, D. A., Mannon, P., Kobayashi, M., Walsh, J. H., Solomon, T. E., and Reeve, J. R. Jr. (2000b). Primary structures of PYY, [Pro(34)]PYY, and PYY-(3-36) confer different conformations and receptor selectivity. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G126-G131.
59. Kimmel, J. R., Hayden, L. J., and Pollock, H. G. (1975). Isolation and characterization of a new pancreatic polypeptide hormone. J. Biol. Chem. 250, 9369-9376.
60. Kirby, D. A., Boublik, J. H., and Rivier, J. E. (1993a). Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions. J. Med. Chem. 36, 3802-3808.
61. Kirby, D. A., Koerber, S. C., Craig, A. G., Feinstein, R. D., Delmas, L., Brown, M. R., et al. (1993b). Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues. J. Med. Chem. 36, 385-393.
62. Koglin, N., Zorn, C., Beumer, R., Cabrele, C., Bubert, C., Sewald, N., et al. (2003). Analogues of neuropeptide Y containing beta-aminocyclopropane carboxylic acids are the shortest linear peptides that are selective for the Y1 receptor. Angew. Chem. Int. Ed. Engl. 42, 202-205.
63. Larhammar, D. (1996). Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept. 65, 165-174.
64. Larhammar, D., and Salaneck, E. (2004). Molecular evolution of NPY receptor subtypes. Neuropeptides 38, 141-151.
65. Larhammar, D., Wraith, A., Berglund, M. M., Holmberg, S. K., and Lundell, I. (2001). Origins of the many NPY-family receptors in mammals. Peptides 22, 295-307.
66. Lee, C. C., and Miller, R. J. (1998). Is there really an NPY Y3 receptor?. Regul. Pept. 75-76, 71-78.
67. Lerch, M., Mayrhofer, M., and Zerbe, O. (2004). Structural similarities of micelle-bound peptide YY (PYY) and neuropeptide Y (NPY) are related to their affinity profiles at the Y receptors. J. Mol. Biol. 339, 1153-1168.
68. Lindner, D., Stichel, J., and Beck-Sickinger, A. G. (2008a). Molecular recognition of the NPY hormone family by their receptors. Nutrition 24, 907-917.
69. Lindner, D., Van Dieck, J., Merten, N., Morl, K., Gunther, R., Hofmann, H. J., et al. (2008b). GPC receptors and not ligands decide the binding mode in neuropeptide Y multireceptor/multiligand system. Biochemistry 47, 5905-5914.
70. Lindner, D., Walther, C., Tennemann, A., and Beck-Sickinger, A. G. (2009). Functional role of the extracellular N-terminal domain of neuropeptide Y subfamily receptors in membrane integration and agonist-stimulated internalization. Cell. Signal. 21, 61-68.
71. Lundberg, J. M., Tatemoto, K., Terenius, L., Hellstrom, P. M., Mutt, V., Hokfelt, T., et al. (1982). Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility. Proc. Natl. Acad. Sci. U.S.A. 79, 4471-4475.
72. Lundell, I., Blomqvist, A. G., Berglund, M. M., Schober, D. A., Johnson, D., Statnick, M. A., et al. (1995). Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J. Biol. Chem. 270, 29123-29128.
73. Lunniss, G. E., Barnes, A. A., Barton, N., Biagetti, M., Bianchi, F., Blowers, S. M., et al. (2009). The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists. Bioorg. Med. Chem. Lett. 19, 4022-4025.
74. Lunniss, G. E., Barnes, A. A., Barton, N., Biagetti, M., Bianchi, F., Blowers, S. M., et al. (2010). The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists. Bioorg. Med. Chem. Lett. 20, 7341-7344.
75. Matsumoto, M., Nomura, T., Momose, K., Ikeda, Y., Kondou, Y., Akiho, H., et al. (1996a). Inactivation of a novel neuropeptide Y/peptide YY receptor gene in primate species. J. Biol. Chem. 271, 27217-27220.
76. Matsumoto, S., Basil, J., Jetton, A. E., Lehman, M. N., and Bittman, E. L. (1996b). Regulation of the phase and period of circadian rhythms restored by suprachiasmatic transplants. J. Biol. Rhythms 11, 145-162.
77. Merten, N., Lindner, D., Rabe, N., Rompler, H., Morl, K., Schoneberg, T., et al. (2007). Receptor subtype-specific docking of Asp6.59 with C-terminal arginine residues in Y receptor ligands. J. Biol. Chem. 282, 7543-7551.
78. Michel, M. C., Beck-Sickinger, A., Cox, H., Doods, H. N., Herzog, H., Larhammar, D., et al. (1998). XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 50, 143-150.
79. Misra, S., Murthy, K. S., Zhou, H., and Grider, J. R. (2004). Coexpression of Y1, Y2, and Y4 receptors in smooth muscle coupled to distinct signaling pathways. J. Pharmacol. Exp. Ther. 311, 1154-1162.
80. Mittapalli, G. K., Vellucci, D., Yang, J., Toussaint, M., Brothers, S. P., Wahlestedt, C., et al. (2012). Synthesis and SAR of selective small molecule neuropeptide Y Y2 receptor antagonists. Bioorg. Med. Chem. Lett. 22, 3916-3920.
81. Moriya, R., Fujikawa, T., Ito, J., Shirakura, T., Hirose, H., Suzuki, J., et al. (2010). Pancreatic polypeptide enhances colonic muscle contraction and fecal output through neuropeptide Y Y4 receptor in mice. Eur. J. Pharmacol. 627, 258-264.
82. Mullins, D., Adham, N., Hesk, D., Wu, Y., Kelly, J., Huang, Y., et al. (2008). Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand. Eur. J. Pharmacol. 601, 1-7.
83. Mullins, D., Kirby, D., Hwa, J., Guzzi, M., Rivier, J., and Parker, E. (2001). Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo. Mol. Pharmacol. 60, 534-540.
84. Neumoin, A., Mares, J., Lerch-Bader, M., Bader, R., and Zerbe, O. (2007). Probing the formation of stable tertiary structure in a model miniprotein at atomic resolution: determinants of stability of a helical hairpin. J. Am. Chem. Soc. 129, 8811-8817.
85. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., et al. (2000). Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289, 739-745.
86. Parker, E. M., Babij, C. K., Balasubramaniam, A., Burrier, R. E., Guzzi, M., Hamud, F., et al. (1998). GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists. Eur. J. Pharmacol. 349, 97-105.
87. Parker, E. M., Balasubramaniam, A., Guzzi, M., Mullins, D. E., Salisbury, B. G., Sheriff, S., et al. (2000). [D-Trp(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intake. Peptides 21, 393-399.
88. Parker, M. S., Sah, R., Balasubramaniam, A., Sallee, F. R., Zerbe, O., and Parker, S. L. (2011). Non-specific binding and general cross-reactivity of Y receptor agonists are correlated and should importantly depend on their acidic sectors. Peptides 32, 258-265.
89. Pedersen, S. L., Holst, B., Vrang, N., and Jensen, K. J. (2009). Modifying the conserved C-terminal tyrosine of the peptide hormone PYY3-36 to improve Y2 receptor selectivity. J. Pept. Sci. 15, 753-759.
90. Pittner, R. A., Moore, C. X., Bhavsar, S. P., Gedulin, B. R., Smith, P. A., Jodka, C. M., et al. (2004). Effects of PYY[3-36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord. 28, 963-971.
91. Potter, E. K., Mitchell, L., Mccloskey, M. J., Tseng, A., Goodman, A. E., Shine, J., et al. (1989). Pre- and postjunctional actions of neuropeptide Y and related peptides. Regul. Pept. 25, 167-177.
92. Raposinho, P. D., Pierroz, D. D., Broqua, P., White, R. B., Pedrazzini, T., and Aubert, M. L. (2001). Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. Mol. Cell. Endocrinol. 185, 195-204.
93. Rodriguez, M., Audinot, V., Dromaint, S., Macia, C., Lamamy, V., Beauverger, P., et al. (2003). Molecular identification of the long isoform of the human neuropeptide Y Y5 receptor and pharmacological comparison with the short Y5 receptor isoform. Biochem. J. 369, 667-673.
94. Rudolf, K., Eberlein, W., Engel, W., Wieland, H. A., Willim, K. D., Entzeroth, M., et al. (1994). The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. 271, R11-R13.
95. Rueeger, H., Rigollier, P., Yamaguchi, Y., Schmidlin, T., Schilling, W., Criscione, L., et al. (2000). Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists. Bioorg. Med. Chem. Lett. 10, 1175-1179.
96. Sainsbury, A., Shi, Y. C., Zhang, L., Aljanova, A., Lin, Z., Nguyen, A. D., et al. (2010). Y4 receptors and pancreatic polypeptide regulate food intake via hypothalamic orexin and brain-derived neurotropic factor dependent pathways. Neuropeptides 44, 261-268.
97. Salaneck, E., Holmberg, S. K., Berglund, M. M., Boswell, T., and Larhammar, D. (2000). Chicken neuropeptide Y receptor Y2: structural and pharmacological differences to mammalian Y2(1). FEBS Lett. 484, 229-234.
98. Saldanha, S. A., Brothers, S. P., Spicer, T., Cameron, M., Mercer, B. A., Chase, P., et al. (2009). "Probe report for NPY-Y2 receptor antagonists," in Probe Reports from the NIH Molecular Libraries Program [Internet] (Bethesda, MD: National Center for Biotechnology Information). Available at: http://www.ncbi.nlm.nih.gov/books/NBK47354/ [updated August 6, 2010].
99. Sautel, M., Martinez, R., Munoz, M., Peitsch, M. C., Beck-Sickinger, A. G., and Walker, P. (1995). Role of a hydrophobic pocket of the human Y1 neuropeptide Y receptor in ligand binding. Mol. Cell. Endocrinol. 112, 215-222.
100. Sautel, M., Rudolf, K., Wittneben, H., Herzog, H., Martinez, R., Munoz, M., et al. (1996). Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor. Mol. Pharmacol. 50, 285-292.
101. Schloegl, H., Percik, R., Horstmann, A., Villringer, A., and Stumvoll, M. (2011). Peptide hormones regulating appetite - focus on neuroimaging studies in humans. Diabetes Metab. Res. Rev. 27, 104-112.
102. Schober, D. A., Van Abbema, A. M., Smiley, D. L., Bruns, R. F., and Gehlert, D. R. (1998). The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist for the human pancreatic polypeptide-preferring (NPY Y4) receptor. Peptides 19, 537-542.
103. Schwartz, T. W. (2006). Y2/Y4 Selective Receptor Agonists for Therapeutic Intervention. Patent GB20060018812.2.
104. Shoblock, J. R., Welty, N., Nepomuceno, D., Lord, B., Aluisio, L., Fraser, I., et al. (2010). In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2- pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptor. Psychopharmacology (Berl) 208, 265-277.
105. Sjodin, P., Holmberg, S. K., Akerberg, H., Berglund, M. M., Mohell, N., and Larhammar, D. (2006). Re-evaluation of receptor-ligand interactions of the human neuropeptide Y receptor Y1: a site-directed mutagenesis study. Biochem. J. 393, 161-169.
106. Soll, R. M., Dinger, M. C., Lundell, I., Larhammer, D., and Beck-Sickinger, A. G. (2001). Novel analogues of neuropeptide Y with a preference for the Y1-receptor. Eur. J. Biochem. 268, 2828-2837.
107. Sousa, D. M., Baldock, P. A., Enriquez, R. F., Zhang, L., Sainsbury, A., Lamghari, M., et al. (2012). Neuropeptide Y Y1 receptor antagonism increases bone mass in mice. Bone 51, 8-16.
108. Stanley, B. G., Kyrkouli, S. E., Lampert, S., and Leibowitz, S. F. (1986). Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 7, 1189-1192.
109. Starback, P., Wraith, A., Eriksson, H., and Larhammar, D. (2000). Neuropeptide Y receptor gene y6: multiple deaths or resurrections? Biochem. Biophys. Res. Commun. 277, 264-269.
110. Suzuki, K., Simpson, K. A., Minnion, J. S., Shillito, J. C., and Bloom, S. R. (2010). The role of gut hormones and the hypothalamus in appetite regulation. Endocr. J. 57, 359-372.
111. Swanson, D. M., Wong, V. D., Jablonowski, J. A., Shah, C., Rudolph, D. A., Dvorak, C. A., et al. (2011). The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y(2) receptor. Bioorg. Med. Chem. Lett. 21, 5552-5556.
112. Tatemoto, K. (1982). Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc. Natl. Acad. Sci. U.S.A. 79, 5485-5489.
113. Tatemoto, K., and Mutt, V. (1980). Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 285, 417-418.
114. Thiele, T. E., Marsh, D. J., Ste Marie, L., Bernstein, I. L., and Palmiter, R. D. (1998). Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature 396, 366-369.
115. Verdine, G. L., and Walensky, L. D. (2007). The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 13, 7264-7270.
116. Wahlestedt, C., Yanaihara, N., and Hakanson, R. (1986). Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides. Regul. Pept. 13, 307-318.
117. Walther, C., Morl, K., and Beck-Sickinger, A. G. (2011). Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development. J. Pept. Sci. 17, 233-246.
118. Wharton, J., Gordon, L., Byrne, J., Herzog, H., Selbie, L. A., Moore, K., et al. (1993). Expression of the human neuropeptide tyrosine Y1 receptor. Proc. Natl. Acad. Sci. U.S.A. 90, 687-691.
119. Widdowson, P. S. (1993). Quantitative receptor autoradiography demonstrates a differential distribution of neuropeptide-Y Y1 and Y2 receptor subtypes in human and rat brain. Brain Res. 631, 27-38.
120. Widdowson, P. S., Buckingham, R., and Williams, G. (1997). Distribution of [Leu31,Pro34]NPY-sensitive, BIBP3226-insensitive [125I]PYY(3-36) binding sites in rat brain: possible relationship to Y5 NPY receptors. Brain Res. 778, 242-250.
121. Wieland, H. A., Engel, W., Eberlein, W., Rudolf, K., and Doods, H. N. (1998). Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br. J. Pharmacol. 125, 549-555.
122. Zhang, L., Bijker, M. S., and Herzog, H. (2011). The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol. Ther. 131, 91-113.
123. Ziemek, R., Schneider, E., Kraus, A., Cabrele, C., Beck-Sickinger, A. G., Bernhardt, G., et al. (2007). Determination of affinity and activity of ligands at the human neuropeptide Y Y4 receptor by flow cytometry and aequorin luminescence. J. Recept. Signal Transduct. Res. 27, 217-233.
124. Zukowska-Grojec, Z., Karwatowska-Prokopczuk, E., Rose, W., Rone, J., Movafagh, S., Ji, H., et al. (1998). Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ. Res. 83, 187-195.
125. Zwanziger, D., Bohme, I., Lindner, D., and Beck-Sickinger, A. G. (2009). First selective agonist of the neuropeptide Y1-receptor with reduced size. J. Pept. Sci. 15, 856-866.